
    
      In this open study, 30 patients with ICDs, will be treated with 18 mg per day of nalmefene
      during 3 months.

      Patients will be evaluated 2 times: at inclusion visit (J0) and 3 months after (at the end of
      the study, +3months).

      At each time, patients will have :

        -  a clinical and neurological evaluation

        -  neuropsychological tests for cognitive, depression and TCI evaluations.

        -  blood sample to test hepatic and renal functions

        -  tolerance evaluation with a list of adverse events/effects

      Patients will be contacted 3 times by phone: 2 weeks after inclusion, 1 month after inclusion
      and 2 months after inclusion, to note the presence of adverse events.
    
  